We appreciate the comments of Vani et al. (1) in response to our PNAS article (2). In general, we agree with their remarks. Tuberculosis (TB) is a complex disease that, in many ways, can be viewed as a disease of poverty, often accompanied by coinfections and various risk factors in different parts of the world. All of the processes they describe can be captured, more or less, by the parameters of the model. The challenge is to get the parameter values right for different settings. That is not easy because sufficient data are generally not available. We therefore tend to rely on stock estimates made for Europe, the US, and India (made, incidentally, in populations with some level of smokers).
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Vani et al. (1) do not explore the interesting question of how these various risk factors affect control programs. One question is whether risks are stable, increasing, or decreasing in any population. For instance, smoking rates in India have been stable for decades, and, arguably, TB is more or less at equilibrium with respect to the adverse effects of tobacco. Vani et al. (1) may also not be aware that factors that increase rates of progression to active disease work with rather than against chemotherapy programs.
Every mathematical model is a simplification of reality and ideally is designed to explore specific scientific questions of interest. Our purpose was to examine the potential benefits, particularly relative benefits, of different aspects of the Bill and Melinda Gates Foundation portfolio of novel TB vaccines, drug regimes, and diagnostics at a global level, and we chose our model accordingly. Our results are optimistic; we assume 100% coverage instantaneously in 2015. We agree that additional factors may affect local results. If countries want to consider particular intervention strategies, then the relevant local factors, socioeconomic conditions, and epidemiology need to be taken into account. a,b,1 
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